Bitcoin's recovery is challenged by rising long-term U.S. Treasury yields after the Federal Reserve raised interest rates by 25 basis points to a 3.75%-4% range and the Senate narrowly rejected advancing the CLARITY Act. Ten- and 30-year Treasury yields increased sharply, making interest-bearing assets more attractive compared to Bitcoin, which offers no yield. Analysts note that while buying interest in Bitcoin continues, it has diminished as yields rise, highlighting the complex impact of bond market movements versus scheduled Fed decisions. The recent yield increase may slow Bitcoin's recovery but has not yet reversed it.
Bitcoin's recovery amid rising U.S. Treasury yields is presented here with Pluang's cryptocurrency market data for context. For readers following cryptocurrency markets, as of Sep 29, 2026 03:53 WIB, breadth showed 10 out of 50 major cryptocurrencies rose while 39 fell. Notable movers include BAL with a 1-day change of +11.14%, COTI down -12.73%, and UNI down -9.99%.
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
In early November, Sui will unlock a tranche of tokens ranging from 2.07 million to 22.6 million SUI, representing up to 0.55% of the circulating supply. This unlock is part of a long-term vesting schedule with a 12-month cliff and 72 months of linea...
Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...
Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAM...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
